Our Pipeline

OUR PIPELINE

Rhizen’s pipeline consists of internally discovered novel small molecule programs aimed at developing innovative therapies for Oncology

Asset & Target		Concept	Partners & Rights
	Umbralisib/TGR-1202 * PI3Kδ Inhibitor (Oral)	r/r MZL, monotherapy Now approved by US FDA r/r FL, monotherapy Front-line and r/r CLL/SLL, combo with Ublituximab (anti-CD20 Mab)	TG Therapeutics	WW rights to TGTX Rhizen retains India market and global supply
Potentially a best in class PI3Kδ inhibitor with superior safety and additional CK1ε activity which further helps in mitigating immune side effects.
	Tenalisib/RP-6530 # PI3Kδ/γ Inhibitor (Oral)	r/r PTCL and CTCL, mono and combo with Romidepsin AML and Solid tumors	Curon	Gr. China rights to Curon Rhizen to partner other major markets
Dual activity on both δ/γ isoforms with potentially class leading safety and additional activity on SIK3 which adds to Tenalisib’s efficacy.
	RP3128: SOCE/CRAC Inhibitor (Oral)+	Asthma, COPD, Mucositis,Dermatitis & IBD
Differentiated best in class asset with broad Anti-Inflammatory potential across multiple indications.
	RP7214: DHODH Inhibitor (Oral)** +	AML Solid tumors MS, RA, Psoriasis Covid-19
Pyrimidine synthesis inhibitor with broad potential across multiple tumor types. Inhibits differentiation of AML blast cells.
	cMet Inhibitor (Oral)+	NSCLC, HCC, RCC
cMET exon 14 mut specific inhibitor with superior liver distribution. Potential for monotherapy and combination with VEGF inhibitors.
	Differentiated PARP Inhibitor (Oral, IV)+	Multiple Cancers
Broad platform PARP inhibitor program with significant differentiation potential and combination with other synthetically lethal mechanisms.
	Differentiated CDK 4/6 Inhibitor (Oral, IV)+	Multiple Cancers
Broad cell cycle inhibitor program. Initial lead focused on CDK 4/6 with differentiation vis a vis existing late stage/commercial assets.
	DDR Pathway - Novel Target+	Multiple Cancers
Novel first in class program that has monotherapy potential across tumor types and can synergistically combine with PARP inhibitors.
	RV1001, PI3Kδ Inhibitor (Veterinary) +	Canine Lymphoma
First in class veterinary asset targeted towards canine lymphomas and solid tumors. Ready for commercialization with MUMS designation.

*Umbralisib licensed at clinic-ready stage; TGTX drove subsequent clinical development of the asset
**COVID-19 US IND accepted in Nov 2020
#Tenalisib licensed at mid-Ph2 stage
+ Rhizen currently retains global rights

Our Pipeline

OUR PIPELINE

Cookie Policy